au sommaire

    1. OMS (2004). "Exposures that may have put a person at risk of becoming infected with influenzainfluenza A(H5N1)." Organisation Mondiale de la SantéOrganisation Mondiale de la Santé.
    2. OMS (2005). "Recommended laboratory tests to identify avian influenza A virus in specimens from humans." Organisation Mondiale de la Santé.
    3. OMS (2006). "Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO." Organisation Mondiale de la Santé.
    4. UPMC (2005). "Peramivir: Single Dose Prophylaxis for Flu?" Center for Biosecurity of UPMC, for a briefing on Capitol Hill.
    5. Alexander DJDJ, Van RK and Pensaert M (2000). "A review of avian influenza in different bird species." Veterinary microbiology : (Amsterdam) 74(1-2): 3-13.
    6. Amonsin A, Payungporn S, Theamboonlers A, Thanawongnuwech R, Suradhat S, Pariyothorn N, Tantilertcharoen R, Damrongwantanapokin S, Buranathai C, Chaisingh A, Songserm T and Poovorawan Y (2005). "Genetic characterization of H5N1 influenza A viruses isolated from zoo tigers in Thailand." Virology 344(2): 480-491.
    7. Apisarnthanarak A, Erb S, Stephenson I, Katz JM, Chittaganpitch M, Sangkitporn S, Kitphati R, Thawatsupha P, Waicharoen S, Pinitchai U, Apisarnthanarak P, Fraser VJ and Mundy LM (2005). "Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to Avian influenza (H5N1) in a tertiary care center." Clin Infect Dis 40(2): e16-8.
    8. Apisarnthanarak A, Kitphati R, Thongphubeth K, Patoomanunt P, Anthanont P, Auwanit W, Thawatsupha P, Chittaganpitch M, Saeng-Aroon S, Waicharoen S, Apisarnthanarak P, Storch GA, Mundy LM and Fraser VJ (2004). "Atypical avian influenza (H5N1)." Emerg Infect Dis 10(7): 1321-4.
    9. Bantia S, Arnold CS, Parker CDCD, Upshaw R and Chand P (2005). "Anti-influenza virus activity of peramivir in mice with single intramuscular injection." AntiviralAntiviral Res.
    10. Beby-Defaux A, Giraudeau G, Bouguermouh S and Agius G (2003). "La grippe humaine: aspects virologiques, épidémiologie et diagnostic virologique. (Influenza: virological aspects, epidemiology and virological diagnosis)." Médecine et maladies infectieuses 33(3): 134-142.
    11. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, Nicoll A, Touch S and Yuen KY (2005). "Avian influenza A (H5N1) infection in humans." N Engl J Med 353(13): 1374-85.
    12. Bennink JR and Palmore TN (2004). "The promise of siRNAs for the treatment of influenza." Trends Mol Med 10(12): 571-4.
    13. Boibieux A, Bouhour D, Biron F, Chidiac C and Peyramond D (1998). "La grippe aviaire de Hong Kong. (Avian influenza in Hong Kong)." Médecine et maladies infectieuses 28(2): 193-194.
    14. BridgesBridges CB, Katz JM, Seto WH, Chan PKS, Tsang D, Ho W, Mak KH, Lim W, Tam JS, Clarke M, Williams SG, Mounts AW, Bresee JS, Conn LA, Rowe T, Hu-Primmer J, Abernathy RA, Xiuhua LU, Cox NJ and Fukuda K (2000). "Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong." The Journal of infectious diseases 181(1): 344-348.
    15. Bridges CB, Lim W, Hu-Primmer J, Sims L, Fukuda K, Mak KH, Rowe T, Thompson WW, Conn L, Lu X, Cox NJ and Katz JM (2002). "Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998." J Infect Dis 185(8): 1005-10.
    16. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ and Klimov AI (2005). "IncidenceIncidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern." Lancet 366(9492): 1175-81.
    17. Butt KM, Smith GJ, Chen H, Zhang LJ, Leung YH, Xu KM, Lim W, Webster RG, Yuen KY, Peiris JS and Guan Y (2005). "Human Infection with an Avian H9N2 Influenza A Virus in Hong Kong in 2003." J Clin Microbiol 43(11): 5760-7.
    18. Chan PK (2002). "Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997." Clin Infect Dis 34 Suppl 2: S58-64.
    19. Chand P, Babu YS, Bantia S, Rowland S, Dehghani A, Kotian PL, Hutchison TL, Ali S, Brouillette W, El-Kattan Y and LinLin TH (2004). "Syntheses and neuraminidaseneuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives." J Med Chem 47(8): 1919-29.
    20. Chand P, Bantia S, Kotian PL, El-Kattan Y, Lin TH and Babu YS (2005). "Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamiviroseltamivir and zanamivirzanamivir in vivo." Bioorg Med Chem 13(12): 4071-7.
    21. Cheng X, Liu J, He J and Shan F (2002). "Virological and serological surveys for H9N2 subtype of influenza A virus in chickens and men in Shenzhen city." Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 16(4): 319-21.
    22. Chokephaibulkit K, Uiprasertkul M, Puthavathana P, Chearskul P, Auewarakul P, Dowell SF and Vanprapar N (2005). "A child with avian influenza A (H5N1) infection." Pediatr Infect Dis J 24(2): 162-6.
    23. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S, Sawanpanyalert P, Kijphati R, Lochindarat S, Srisan P, Suwan P, Osotthanakorn Y, Anantasetagoon T, Kanjanawasri S, Tanupattarachai S, Weerakul J, Chaiwirattana R, Maneerattanaporn M, Poolsavathitikool R, Chokephaibulkit K, Apisarnthanarak A and Dowell SF (2005). "Human disease from influenza A (H5N1), Thailand, 2004." Emerg Infect Dis 11(2): 201-9.
    24. Claas ECJ, Van RK and Pensaert M (2000). "Pandemic influenza is a zoonosis, as it requires introduction of avian-like gene segments in the human population." Veterinary microbiology : (Amsterdam) 74(1-2): 133-139.
    25. Coiras MT, Aguilar JC, Galiano M, Carlos S, Gregory V, Lin YP, Hay A and Perez-Brena P (2001). "Rapid molecular analysis of the haemagglutinin gene of human influenza A H3N2 viruses isolated in Spain from 1996 to 2000." Archives of virology 146(11): 2133-2147.
    26. Collins RA, Ko L-S, So K-L, Ellis T, Lau L-T and Cheung HOIYUA (2002). "Detection of highly pathogenic and low pathogenic avian influenza subtype H5 (Eurasian lineage) using NASBA." Journal of virological methods 103(2): 213-225.
    27. Cooper N, Sutton AJ, Abrams KR, Wailoo A, Turner DA, Nicholson KGKG and Hansen L (2003). "Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. Commentary." BMJ. British medical journal : (International ed.) 326(7401): 1235-1240.
    28. de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, Nguyen BH, Beld M, Le TP, Truong HK, Nguyen VV, Tran TH, Do QH and Farrar J (2005). "Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma." N Engl J Med 352(7): 686-91.
    29. de Jong MD and Hien TT (2006). "Avian influenza A (H5N1)." J Clin Virol 35(1): 2-13.
    30. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH and Farrar J (2005). "Oseltamivir resistance during treatment of influenza A (H5N1) infection." N Engl J Med 353(25): 2667-72.
    31. Dreitlein WB, Maratos J and Brocavich J (2001). "Zanamivir and oseltamivir : Two new options for the treatment and prevention of Influenza." Clinical therapeutics 23(3): 327-355.
    32. Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C and Ward P (2003). "Safety and pharmacology of oseltamivir in clinical use." Drug safety 26(11): 787-801.
    33. Ellis JS and Zambon MC (2001). "Combined PCR-heteroduplex mobility assay for detection and differentiation of influenza A viruses from different animal species." Journal of clinical microbiology 39(11): 4097-4102.
    34. Fleming DM (2001). "Managing influenza : Amantadine, rimantadine and beyond." International journal of clinical practice : (Esher) 55(3): 189-195.
    35. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M and Osterhaus AD (2004). "Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome." Proc Natl Acad Sci U S A 101(5): 1356-61.
    36. Ge Q, Eisen HN and Chen J (2004). "Use of siRNAs to prevent and treat influenza virus infection." Virus Res 102(1): 37-42.
    37. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN and Chen J (2004). "Inhibition of influenza virus production in virus-infected mice by RNA interference." Proc Natl Acad Sci U S A 101(23): 8676-81.
    38. Grose C and Chokephaibulkit K (2004). "Avian influenza virus infection of children in Vietnam and Thailand." Pediatr Infect Dis J 23(8): 793-4.
    39. Gubareva LV (2004). "Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors." Virus Res 103(1-2): 199-203.
    40. Hayden F and Croisier A (2005). "Transmission of avian influenza viruses to and between humans." J Infect Dis 192(8): 1311-4.
    41. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE and Monto AS (2004). "Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets." J Infect Dis 190(9): 1627-30.
    42. Ilyushina NA, Govorkova EA and Webster RG (2005). "Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia." Virology 341(1): 102-6.
    43. Institut Pasteur, Réseau national de santé publique, Groupes régionaux d'observation de la grippe, Réseau Sentinelles de l'INSERM and Direction générale de la Santé (1998). "Données sur la grippe à virus A (H5N1) à Hong Kong et sur le début de grippe à virus A (H3N2) en France." Bulletin Epidemiologique Hebdomadaire 8: 31.
    44. Ison MG, Gnann JW, Jr., Nagy-Agren S, Treannor J, Paya C, Steigbigel R, Elliott M, Weiss HL and Hayden FG (2003). "Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza." Antivir Ther 8(3): 183-90.
    45. Iwasaki T, Itamura S, Nishimura H, Sato Y, Tashiro M, Hashikawa T and Kurata T (2004). "Productive infection in the murine central nervous system with avian influenza virus A (H5N1) after intranasal inoculation." Acta Neuropathol (Berl) 108(6): 485-92.
    46. Kaiser L (2001). "Inhibiteurs de la neuraminidase et traitement de la grippe: un bénéfice au-delà de la résolutionrésolution des symptômes ? : Maladies infectieuses. (Treatment of Influenza with neuraminidase inhibitors: is there a benefit beyoud symptom resolution ?)." Médecine et hygiène 59(2369): 2296-2300 3 .
    47. Kaji M, Fukuda T, Tanaka M and Aizawa H (2005). "A side effect of neuraminidase inhibitor in a patient with liver cirrhosis." J Infect Chemother 11(1): 41-3.
    48. Katz JM, Lim W, Bridges CB, Rowe T, Hu-Primmer J, Lu X, Abernathy RA, Clarke M, Conn L, Kwong H, Lee M, Au G, Ho YY, Mak KH, Cox NJ and Fukuda K (1999). "Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts." J Infect Dis 180(6): 1763-70.
    49. Keawcharoen J, Oraveerakul K, Kuiken T, Fouchier RA, Amonsin A, Payungporn S, Noppornpanth S, Wattanodorn S, Theambooniers A, Tantilertcharoen R, Pattanarangsan R, Arya N, Ratanakorn P, Osterhaus DM and Poovorawan Y (2004). "Avian influenza H5N1 in tigers and leopards." Emerg Infect Dis 10(12): 2189-91.
    50. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N and Kawaoka Y (2004). "Resistant influenza A viruses in children treated with oseltamivir: descriptive study." Lancet 364(9436): 759-65.
    51. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A and Bosman A (2004). "Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands." Lancet 363(9409): 587-93.
    52. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y and Kawaoka Y (2005). "Avian flu: isolationisolation of drug-resistant H5N1 virus." Nature 437(7062): 1108.
    53. Leneva IAIA, Roberts N, Govorkova EA, Goloubeva OG and Webster RG (2000). "The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99." Antiviral research 48(2): 101-115.
    54. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, Rahardjo AP, Puthavathana P, Buranathai C, Nguyen TD, Estoepangestie AT, Chaisingh A, Auewarakul P, Long HTHT, Hanh NT, Webby RJ, Poon LL, Chen H, Shortridge KF, Yuen KY, Webster RG and Peiris JS (2004). "Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia." Nature 430(6996): 209-13.
    55. Liem NT and Lim W (2005). "Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004." Emerg Infect Dis 11(2): 210-5.
    56. Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K, Webster R, Cox N and Hay A (2000). "Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates." Proc Natl Acad Sci U S A 97(17): 9654-8.
    57. Luscher-Mattli M (2000). "Influenza chemotherapy : a review of the present state of art and of new drugs in development: Brief Review." Archives of virology 145(11): 2233-2248.
    58. Macdonald SJ, Cameron R, Demaine DA, Fenton RJ, Foster G, Gower D, Hamblin JN, Hamilton S, Hart GJ, Hill AP, Inglis GG, Jin B, Jones HT, McConnell DB, McKimm-Breschkin J, Mills G, Nguyen V, Owens IJ, Parry N, Shanahan SE, Smith D, Watson KG, Wu WY and Tucker SP (2005). "Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza." J Med Chem 48(8): 2964-71.
    59. Macdonald SJ, Watson KG, Cameron R, Chalmers DK, Demaine DA, Fenton RJ, Gower D, Hamblin JN, Hamilton S, Hart GJ, Inglis GG, Jin B, Jones HT, McConnell DB, Mason AM, Nguyen V, Owens IJ, Parry N, Reece PA, Shanahan SE, Smith D, Wu WY and Tucker SP (2004). "Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a onceonce-weekly dosing regimen." Antimicrob Agents Chemother 48(12): 4542-9.
    60. Masuda H, Suzuki H, Oshitani H, Saito R, Kawasaki S, Nishikawa M and Satoh H (2000). "Incidence of amantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan." Microbiology and immunology 44(10): 833-839.
    61. McClellan K and Perry CM (2001). "Oseltamivir: A review of its use in influenza." Drugs : (Basel) 61(2): 263-283.
    62. McGeer AJ, Lee W, Loeb M, Simor AE, McArthur M, Green K, Benjamin JH and Gardner C (2004). "Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults." Infect Control Hosp Epidemiol 25(11): 955-61.
    63. McKimm-Breschkin JL (2005). "Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance." Treat Respir Med 4(2): 107-16.
    64. McNicholl IR and McNicholl JJ (2001). "Neuraminidase inhibitors : Zanamivir and oseltamivir." (The) Annals of pharmacotherapy 35(1): 57-70.
    65. Meijer A, Valette M, Manuguerra JC, Perez-Brena P, Paget J, Brown C and van der Velden K (2005). "Implementation of the community network of reference laboratories for human influenza in Europe." J Clin Virol 34(2): 87-96.
    66. Mishin VP, Hayden FG and Gubareva LV (2005). "Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors." Antimicrob Agents Chemother 49(11): 4515-20.
    67. Monto AS, Osterhaus ADME, Palache AM, Peiris JSM, Savy VL and StÖHr K (2003). "The role of antivirals in the control of influenza." Vaccine 21(16): 1796-1800.
    68. Moscona A (2005). "Neuraminidase inhibitors for influenza." N Engl J Med 353(13): 1363-73.
    69. Mounts AW, Kwong H, Izurieta HS, Ho Y, Au T, Lee M, Buxton Bridges C, Williams SW, Mak KH, Katz JM, Thompson WW, Cox NJ and Fukuda K (1999). "Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997." J Infect Dis 180(2): 505-8.
    70. Ng EK, Cheng PK, Ng AY, Hoang TL and Lim WW (2005). "Influenza A H5N1 detection." Emerg Infect Dis 11(8): 1303-5.
    71. Nordstrom BL, Oh K, Sacks ST and L'Italien GJ (2004). "Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study." Antivir Ther 9(2): 187-95.
    72. Olsen SJ, Ungchusak K, Sovann L, Uyeki TM, Dowell SF, Cox NJ, Aldis W and Chunsuttiwat S (2005). "Family clustering of avian influenza A (H5N1)." Emerg Infect Dis 11(11): 1799-1801.
    73. Oxford J (2005). "Oseltamivir in the management of influenza." Expert Opin Pharmacother 6(14): 2493-500.
    74. Oxford JS, Bossuyt S, Balasingam S, Mann A, Novelli P and Lambkin R (2003). "Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors." Clinical microbiology and infection 9(1): 1-14.
    75. Payungporn S, Chutinimitkul S, Chaisingh A, Damrongwantanapokin S, Buranathai C, Amonsin A, Theamboonlers A and Poovorawan Y (2006). "Single step multiplex real-time RT-PCR for H5N1 influenza A virus detection." J Virol Methods 131(2): 143-147.
    76. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK and Shortridge KF (1999). "Human infection with influenza H9N2." Lancet 354(9182): 916-7.
    77. Playford EG and Dwyer DE (2002). "Laboratory diagnosis of influenza virus infection." Pathology : (Sydney) 34(2): 115-125.
    78. Puthavathana P, Auewarakul P, Charoenying PCPC, Sangsiriwut K, Pooruk P, Boonnak K, Khanyok R, Thawachsupa P, Kijphati R and Sawanpanyalert P (2005). "Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand." J Gen Virol 86(Pt 2): 423-33.
    79. Puzelli S, Di Trani L, Fabiani C, Campitelli L, De Marco MA, Capua I, Aguilera JF, Zambon M and Donatelli I (2005). "Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003." J Infect Dis 192(8): 1318-22.
    80. Roberts NA (2001). "Anti-influenza drugs and neuraminidase inhibitors." Progress in drug research 56: 195-237.
    81. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ and Katz JM (1999). "Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays." J Clin Microbiol 37(4): 937-43.
    82. Rowe T, Cho DS, Bright RA, Zitzow LA and Katz JM (2003). "Neurological manifestations of avian influenza viruses in mammals." Avian Dis 47(3 Suppl): 1122-6.
    83. Savarino A (2005). "Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza." J Clin Virol 34(3): 170-8.
    84. Schultsz C, Dong VC, Chau NV, Le NT, Lim W, Thanh TT, Dolecek C, de Jong MD, Hien TT and Farrar J (2005). "Avian influenza H5N1 and healthcare workers." Emerg Infect Dis 11(7): 1158-9.
    85. Shinya K, Hatta M, Yamada S, Takada A, Watanabe S, Halfmann P, Horimoto T, Neumann G, Kim JH, Lim W, Guan Y, Peiris M, Kiso M, Suzuki T, Suzuki Y and Kawaoka Y (2005). "Characterization of a human H5N1 influenza A virus isolated in 2003." J Virol 79(15): 9926-32.
    86. Sidwell RW, Bailey KW, Wong MH, Barnard DL and Smee DF (2005). "In vitro and in vivo influenza virus-inhibitory effects of viramidine." Antiviral Res 68(1): 10-7.
    87. Sims LD, Domenech J, Benigno C, Kahn S, Kamata A, Lubroth J, Martin V and Roeder P (2005). "Origin and evolution of highly pathogenic H5N1 avian influenza in Asia." Vet Rec 157(6): 159-64.
    88. Stephenson I, Wood JM, Nicholson KG and Zambon MC (2003). "Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin." J Med Virol 70(3): 391-8.
    89. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K and Cox N (1998). "Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness." Science : (Washington, D.C.) 279(5349): 393-396.
    90. Sun C, Huang H, Feng M, Shi X, Zhang X and Zhou P (2006). "A novel class of potent influenza virus inhibitors: Polysubstituted acylthiourea and its fused heterocycle derivatives." Bioorg Med Chem Lett 16(1): 162-6.
    91. Tanaka H, Park C-H, Ninomiya A, Ozaki H, Takada A, Umemura T and Kida H (2003). "Neurotropism of the 1997 Hong Kong H5N1 influenza virus in mice." Veterinary microbiology : (Amsterdam) 95(1-2): 1-13.
    92. Tompkins SM, Lo CY, Tumpey TM and Epstein SL (2004). "Protection against lethal influenza virus challenge by RNA interference in vivo." Proc Natl Acad Sci U S A 101(23): 8682-6.
    93. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, Nguyen VC, Pham TS, Vo CD, Le TQ, Ngo TT, Dao BK, Le PPPP, Nguyen TT, Hoang TL, Cao VT, Le TG, Nguyen DT, Le HN, Nguyen KT, Le HS, Le VT, Christiane D, Tran TT, Menno de J, Schultsz C, Cheng P, Lim W, Horby P and Farrar J (2004). "Avian influenza A (H5N1) in 10 patients in Vietnam." N Engl J Med 350(12): 1179-88.
    94. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, Zaki SR, Thawatsupha P, Chittaganpitch M, Khontong R, Simmerman JM and Chunsutthiwat S (2005). "Probable person-to-person transmission of avian influenza A (H5N1)." N Engl J Med 352(4): 333-40.
    95. Uyeki TM, Chong YH, Katz JM, Lim W, Ho YY, Wang SS, Tsang TH, Au WW, Chan SC, Rowe T, Hu-Primmer J, Bell JC, Thompson WW, Bridges CB, Cox NJ, Mak KH and Fukuda K (2002). "Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China 1999." Emerg Infect Dis 8(2): 154-9.
    96. Ward P, Small I, Smith J, Suter P and Dutkowski R (2005). "Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic." J Antimicrob Chemother 55 Suppl 1: i5-i21.
    97. Watson KG, Cameron R, Fenton RJ, Gower D, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell D, MacDonald SJ, Mason AM, Nguyen V, Tucker SP and Wu WY (2004). "Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase." Bioorg Med Chem Lett 14(6): 1589-92.
    98. WHO Global Influenza Program (2005). "Evolution of H5N1 Avian Influenza Viruses in Asia." Emerg Infect Dis 11(10).
    99. Wiwanitkit V (2005). "Diarrhoea as a presentation of bird flu infection: a summary on its correlation to outcome in Thai cases." Gut 54(10): 1506.
    100. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG and Govorkova EA (2005). "Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitnessfitness and transmissibility." Antimicrob Agents Chemother 49(10): 4075-84.
    101. Yen HL, Monto AS, Webster RG and Govorkova EA (2005). "Virulence may determine the necessary duration and dosagedosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice." J Infect Dis 192(4): 665-72.
    102. Yuen KY and Wong SS (2005). "Human infection by avian influenza A H5N1." Hong Kong Med J 11(3): 189-99.